SIRT7 Is a Prognostic Biomarker Associated With Immune Infiltration in Luminal Breast Cancer

Abstract

Background: Sirtuin 7 (SIRT7), a protein-coding gene whose abnormal expression and function are associated with carcinogenesis. However, the prognosis of SIRT7 in different breast cancer subtypes and its correlation with tumor-infiltrating lymphocytes remain unclear. Methods: The expression and survival data of SIRT7 in patients with breast cancer were analyzed using Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interaction Analysis (GEPIA), The Human Protein Atlas (HPA), UALCAN, Breast Cancer Gene-Expression Miner (BC-GenExMiner), and Kaplan-Meier plotter databases. Also, the expression correlations between SIRT7 and immune infiltration gene markers were analyzed using TIMER and further verified the results using immunohistochemistry. Results: SIRT7 exhibited higher expression levels in breast cancer tissues than the adjacent normal tissues. SIRT7 expression was significantly correlated with sample type, subclass, cancer stage, menopause status, age, nodal status, estrogen receptor (ER), progesterone receptor (PR), and triple-negative status. High SIRT7 expression was associated with poor prognosis in breast cancer-luminal A [overall survival (OS): hazard ratio (HR) = 1.54, p = 1.70e-02; distant metastasis-free survival (DMFS): HR = 1.56, p = 2.60e-03]. Moreover, the expression of SIRT7 was positively correlated with the expression of IRF5 (M1 macrophages marker, r = 0.165, p = 1.13e-04) and PD1 (T cell exhaustion marker, r = 0.134, p = 1.74e-03). These results suggested that the expression of SIRT7 was related to M1 macrophages and T cell exhaustion infiltration in breast cancer-luminal. Conclusions: These findings demonstrate that the high expression of SIRT7 indicates poor prognosis in breast cancer as well as increased immune infiltration levels of M1 macrophages and T cell exhaustion in breast cancer-luminal. Thus, SIRT7 may serve as a candidate prognostic biomarker for determining prognosis associated with immune infiltration in breast cancer-luminal.

Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer

“…Since inhibition of TIE2 was found to result in inhibition of cancer cell migration and tumour invasion in our previous findings, 39 , 40 the anti-metastatic effect of MSN-siRNA/Apt was assessed in vitro. Notably, Dox was found to impact cell migration and invasion in previous studies; 41 , 42 consequently, Dox was not loaded into the siRNA formulations in our in vitro anti-metastasis study. First, the TIE2 protein expression among different treatments was investigated to determine the knockdown effect of siTIE2.…”

A Histone Acetylation Modulator Gene Signature for Classification and Prognosis of Breast Cancer

“…For the two writers, CLOCK was reported to have a regulatory role in breast cancer tumorigenesis [ 21 , 22 ], while no specific studies have reported the role of GTF3C4 in breast cancer. For the two erasers, overexpression of HDAC2 had a strong effect on breast cancer prognosis [ 23 , 24 , 25 ] while the effect of SIRT7 seems to be controversial [ 26 , 27 , 28 ]. Moreover, the writer genes were found to be more highly expressed in HAM2 than in HAM1 while the erasers showed the opposite trend.…”

Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer

“…The analysis of protein expression levels of SCGB2A1 in UCEC was performed by UALCAN based on the CPTAC database. UALCAN performed the comparison of differential expression between each two groups by using t-tests (22), and similar results from the UALCAN using the same statistical methods have been published previously (23)(24)(25). Differential protein expression of SCGB2A1 between UCEC and normal tissues, and the association between clinical characteristics and protein expression levels of SCGB2A1, were analyzed.…”